Your browser doesn't support javascript.
loading
Benefits of high-dose intravenous immunoglobulin on mortality in patients with severe COVID-19: An updated systematic review and meta-analysis.
Liu, Xiaosheng; Zhang, Yuelun; Lu, Lianfeng; Li, Xiaodi; Wu, Yuanni; Yang, Yang; Li, Taisheng; Cao, Wei.
Affiliation
  • Liu X; Tsinghua-Peking Center for Life Sciences, Beijing, China.
  • Zhang Y; Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China.
  • Lu L; Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
  • Li X; Medical research center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
  • Wu Y; Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
  • Yang Y; Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
  • Li T; Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
  • Cao W; Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Front Immunol ; 14: 1116738, 2023.
Article in En | MEDLINE | ID: mdl-36756131

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulins, Intravenous / COVID-19 Type of study: Clinical_trials / Observational_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: Front Immunol Year: 2023 Document type: Article Affiliation country: China Country of publication: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulins, Intravenous / COVID-19 Type of study: Clinical_trials / Observational_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: Front Immunol Year: 2023 Document type: Article Affiliation country: China Country of publication: Switzerland